Advanced search
Publication Cover
Cancer Investigation Volume 22, 2004 - Issue 5
Submit an article Journal homepage
41
Views
25
CrossRef citations to date
0
Altmetric
Original Article

Salvage Chemotherapy with Mitomycin, Docetaxel, and Irinotecan (MDI Regimen) in Metastatic Pancreatic Adenocarcinoma: A Phase I and II Trial

Michele Reni Department of Radiochemotherapy, San Raffaele H. Scientific Institute, via Olgettina 60, Milan, 20132, Italy
, M.D.,
M. G. Panucci Department of Radiochemotherapy, San Raffaele H. Scientific Institute, via Olgettina 60, Milan, 20132, Italy
, M.D.,
P. Passoni Department of Radiochemotherapy, San Raffaele H. Scientific Institute, via Olgettina 60, Milan, 20132, Italy
, M.D.,
E. Bonetto Department of Radiochemotherapy, San Raffaele H. Scientific Institute, via Olgettina 60, Milan, 20132, Italy
, M.D.,
R. Nicoletti Department of Radiology, San Raffaele H. Scientific Institute, Milan, Italy
, M.D.,
M. Ronzoni Department of Radiochemotherapy, San Raffaele H. Scientific Institute, via Olgettina 60, Milan, 20132, Italy
, M.D.,
A. Zerbi Department of Surgery, San Raffaele H. Scientific Institute, Milan, Italy
, M.D.,
C. Staudacher Department of Surgery, San Raffaele H. Scientific Institute, Milan, Italy
, M.D.,
V. Di Carlo Department of Surgery, San Raffaele H. Scientific Institute, Milan, Italy
, M.D. &
E. Villa Department of Radiochemotherapy, San Raffaele H. Scientific Institute, via Olgettina 60, Milan, 20132, Italy
, M.D. show all
Pages 688-696 | Published online: 10 Nov 2004

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Jie Hua, Si Shi, Dingkong Liang, Chen Liang, Qingcai Meng, Bo Zhang, Quanxing Ni, Jin Xu & Xianjun Yu. (2018) Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?. OncoTargets and Therapy 11, pages 4591-4608.
Read now
Muhammad Wasif Saif. (2014) Advanced stage pancreatic cancer: novel therapeutic options. Expert Review of Clinical Pharmacology 7:4, pages 487-498.
Read now

Articles from other publishers (23)

Barbara Burtness, Mark Powell, Paul Catalano, Jordan Berlin, Darla K. Liles, Andrew E. Chapman, Edith Mitchell & Al B. Benson. (2016) Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer. American Journal of Clinical Oncology 39:4, pages 340-345.
Crossref
Andrea Wang-Gillam, Chung-Pin Li, György Bodoky, Andrew Dean, Yan-Shen Shan, Gayle Jameson, Teresa Macarulla, Kyung-Hun Lee, David Cunningham, Jean F Blanc, Richard A Hubner, Chang-Fang Chiu, Gilberto Schwartsmann, Jens T Siveke, Fadi Braiteh, Victor Moyo, Bruce Belanger, Navreet Dhindsa, Eliel Bayever, Daniel D Von Hoff, Li-Tzong Chen, Clarence Adoo, Thomas Anderson, Jamil Asselah, Alan Azambuja, Carolyn Bampton, Carlos Henrique Barrios, Tanios Bekaii-Saab, Melichar Bohuslav, David Chang, Jen-Shi Chen, Yeu-Chin Chen, Hye Jin Choi, Ik Joo Chung, Vincent Chung, Tibor Csoszi, Antonio Cubillo, Linda DeMarco, Maike de Wit, Tomislav Dragovich, William Edenfield, Luis Enrique Fein, Fábio Franke, Martin Fuchs, Vega Gonzales-Cruz, Alberto Gozza, Rivera Herrero Fernando, Rosario Iaffaioli, Jitka Jakesova, Zsuzsanna Kahan, Misagh Karimi, Jun Suk Kim, Ernesto Korbenfeld, Istvan Lang, Fa-Chyi Lee, Kuan-Der Lee, Lara Lipton, Wen Wee Ma, Laszlo Mangel, Raul Mena, Daniel Palmer, Shubham Pant, Joon Oh Park, Paolo Piacentini, Uwe Pelzer, Javier Gallego Plazas, Cooray Prasad, Kun-Ming Rau, Jean-Luc Raoul, Donald Richards, Paul Ross, Luis Schlittler, Martin Smakal, Vladimira Stahalova, Cora Sternberg, Thomas Seufferlein, Niall Tebbutt, Jeferson Jose Vinholes, Raymond Wadlow, Milkos Wenczl & Mark Wong. (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. The Lancet 387:10018, pages 545-557.
Crossref
BYEONG SEOK SOHN, YOUNG JIN YUH, HONG SUK SONG, BONG-SEOG KIM, KYUNG HEE LEE, JOUNG-SOON JANG & SUNG ROK KIM. (2015) Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer. Oncology Letters 10:2, pages 1204-1210.
Crossref
Marcus Bahra, Florian Lordick, Manfred P. Lutz, Matthias Glanemann & Peter Neuhaus. 2015. Viszeralmedizin. Viszeralmedizin 557 567 .
Hend Ahmed El-Hadaad & Hanan Ahmed Wahba. (2013) Oxaliplatin Plus 5-Fluorouracil and Folinic Acid (OFF) in Gemcitabine-Pretreated Advanced Pancreatic Cancer: A Phase II Study. Journal of Gastrointestinal Cancer 44:3, pages 313-317.
Crossref
Hassan K. Dakik, Daniel J. Moskovic, Peter J. Carlson, Eric P. Tamm, Wei Qiao, Robert A. Wolff, James L. Abbruzzese & David R. Fogelman. (2011) The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemotherapy and Pharmacology 69:2, pages 425-430.
Crossref
. 2012. Facharzt Hämatologie Onkologie. Facharzt Hämatologie Onkologie e1 e61 .
A. Todaka, A. Fukutomi, N. Boku, Y. Onozawa, S. Hironaka, H. Yasui, K. Yamazaki, K. Taku, N. Machida, T. Sakamoto & H. Tomita. (2010) S-1 Monotherapy as Second-line Treatment for Advanced Pancreatic Cancer after Gemcitabine Failure. Japanese Journal of Clinical Oncology 40:6, pages 567-572.
Crossref
Roderich E. Schwarz, Niranjan Awasthi, Srivani Konduri, Danielle Cafasso & Margaret A. Schwarz. (2009) EMAP II-Based Antiangiogenic-Antiendothelial In Vivo Combination Therapy of Pancreatic Cancer. Annals of Surgical Oncology 17:5, pages 1442-1452.
Crossref
Ben LawrenceMichael Findlay. (2010) Systemic therapy for metastatic pancreatic adenocarcinoma. Therapeutic Advances in Medical Oncology 2:2, pages 85-106.
Crossref
Ana Custodio, Javier Puente, Javier Sastre & Eduardo Díaz-Rubio. (2009) Second-line therapy for advanced pancreatic cancer: A review of the literature and future directions. Cancer Treatment Reviews 35:8, pages 676-684.
Crossref
Chigusa Morizane, Takuji Okusaka, Junji Furuse, Hiroshi Ishii, Hideki Ueno, Masafumi Ikeda, Kohei Nakachi, Mina Najima, Takashi Ogura & Eiichiro Suzuki. (2008) A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology 63:2, pages 313-319.
Crossref
M. Reni, R. Berardi, A. Mambrini, L. Pasetto, S. Cereda, V. D. Ferrari, S. Cascinu, M. Cantore, E. Mazza & S. Grisanti. (2008) A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology 62:4, pages 673-678.
Crossref
M Reni, S Cereda, E Mazza, P Passoni, R Nicoletti, G Balzano, A Zerbi, P G. Arcidiacono, C Staudacher & V Di Carlo. (2008) PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) Regimen as Second-Line Therapy in Patients With Progressive or Recurrent Pancreatic Cancer After Gemcitabine-Containing Chemotherapy. American Journal of Clinical Oncology 31:2, pages 145-150.
Crossref
Dan Laheru, Eric Lutz, James Burke, Barbara Biedrzycki, Sara Solt, Beth Onners, Irena Tartakovsky, John Nemunaitis, Dung Le, Elizabeth Sugar, Kristen Hege & Elizabeth Jaffee. (2008) Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation. Clinical Cancer Research 14:5, pages 1455-1463.
Crossref
Stefan BoeckVolker Heinemann. (2008) The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer. Future Oncology 4:1, pages 41-50.
Crossref
Barbara Burtness, Laurie Thomas, Rebecca Sipples, Meghan McGurk, Saritha Salikooti, Maryanne Christoforou, Gayle Mirto, Ronald Salem, Julieann Sosa, Robert Kloss, Zia Rahman, Gina Chung, Jill Lacy & John R. Murren. (2007) Phase II Trial of Weekly Docetaxel/Irinotecan Combination in Advanced Pancreatic Cancer. The Cancer Journal 13:4, pages 257-262.
Crossref
A Mercalli, V Sordi, R Formicola, M Dandrea, S Beghelli, A Scarpa, V Di Carlo, M Reni & L Piemonti. (2007) A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer. British Journal of Cancer 96:9, pages 1358-1367.
Crossref
Kohei Nakachi, Junji Furuse, Hiroshi Ishii, Ei-ichiro Suzuki & Masahiro Yoshino. (2007) Prognostic Factors in Patients with Gemcitabine-Refractory Pancreatic Cancer. Japanese Journal of Clinical Oncology 37:2, pages 114-120.
Crossref
Gunnar Folprecht, Michael Geißler, Diana Lüftner, Helmut Öttle, Kurt Possinger & Anne C. Regierer. 2007. Facharzt Hämatologie Onkologie. Facharzt Hämatologie Onkologie 573 690 .
H. Oettle, A. Goerke, A. Kaiser, V. Budach & P. Vogel. 2007. Therapiekonzepte Onkologie. Therapiekonzepte Onkologie 713 733 .
M Reni, L Pasetto, G Aprile, S Cordio, E Bonetto, S Dell'oro, P Passoni, L Piemonti, C Fugazza, G Luppi, C Milandri, R Nicoletti, A Zerbi, G Balzano, V Di Carlo & A A Brandes. (2006) Raltitrexed–eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. British Journal of Cancer 94:6, pages 785-791.
Crossref
Patricia A Tang & Malcolm J Moore. (2006) Epidermal Growth Factor Receptor Antagonists in Pancreatic Cancer. American Journal of Cancer 5:4, pages 213-221.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.